Zevra Highlights Plans to Advance IH, Narcolepsy Drug Candidate

Zevra reported progress in 2023, including results from a phase 2 study for idiopathic hypersomnia and plans to expand into narcolepsy.

Related Keywords

,Neilf Mcfarlane ,Drug Administration ,Zevra Therapeutics Inc ,Investigational New Drug ,Therapeutics Inc ,Epworth Sleepiness ,Idiopathic Hypersomnia Severity Scale ,Sleep Inertia Visual Analog Scale ,Brain Fog ,